New approaches to the treatment of congenital adrenal hyperplasia.
Merke
D P
DP
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md 20892-1862, USA.
Cutler
G B
GB
D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D000365:Age Determination by Skeleton; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002648:Child; D003534:Cyproterone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005438:Fludrocortisone / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use*; D006128:Growth; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D013738:Testolactone / Q000627:therapeutic use*
D000726:Androgen Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D013738:Testolactone; D005485:Flutamide; D003534:Cyproterone; D005438:Fludrocortisone; D006854:Hydrocortisone